GMP Compliance Trends: An Industry Perspective Mitchell W. Manning Priorities Limited

Slides:



Advertisements
Similar presentations
TIME PAST O’CLOCK TO HALF TO HALF O’CLOCK PAST.
Advertisements

Engaging with Employers UKSPA Member Meeting Oct 6th/7th John Holton Strategy Director Cogent Sector Skills Council.
What time is it? What’s the time?
VALIDATION OF COMPUTERISED SYSTEMS IN THE PHARMACEUTICAL INDUSTRY Matt Safi Product manager.
Sixteen Squared. 256 One Squared 1 Three Cubed.
Multiplication Facts 9 through x 5= 50 Number One.
Vetting and managing subcontractors – avoiding the bear traps Wayne Hughes HQN.
What time is it? Coo-Coo one o'clock a quarter to seven
NUMBERS. 1 ONE Mariana T. Vilas Boas, Digital.
Roles and Functions of the Community and Public Health Nurse
PRESENTATION TO THE NATIONAL STAKEHOLDERS MEETING OF THE EAC REGIONAL STEERING COMMITTEE BY THE GMP TWG Presented by: Uganda, Kenya, United Republic of.
APIs – global business developments Gian Mario Baccalini EFCG Board Member, Chairman of EFCG Pharma Business Committee President, B&P Development Srl,
What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.
Human Resource Management Lecture-25. Career (cont..)
Global Theodolite Industry Research Report 2015 Published By QYResearch Contact US: Web: Blog:
Global Uvinul 3034 Industry Research Report 2015 Published By QYResearch Contact US: Web: Blog:
4 4 By: A. Shukr, M. Alnouri. Many new project managers have trouble looking at the “big picture” and want to focus on too many details. Project managers.
The Health Care Sector Analysts: Heather Hund and Emily Butler.
1 1 PDUFA & FDA Legislation FDA Regulatory & Compliance Symposium August 2006 Marc Wilenzick, Moderator for Panel: Dan Carpenter, Harvard Dept. of Government.
Good Clinical Practice GCP
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
The views expressed in this presentation do not necessarily reflect those of the Federal Reserve Bank of New York or the Federal Reserve System Association.
ISPE China Annual Conference 2012 April Beijing 1 Current situation and solutions of Chinese GMP implementation Wu Jun
ISPE Central Canada Chapter Annual Meeting September 28, 2006 Yvon R. Tessier Pharmaceutical contract manufacturing challenges.
Lecture held on the Food Safety Conference March 2004 Dublin 1 Control Methods and Organisation of Official Controls in Hungary Dr. Peter A. BIACS,
CLICK THE NUMBERS IN SEQUENCE
Achievements and impacts of WHO prequalification to date MSF perspective Carine Werder MSF international pharmacist coordinator Geneva, 11 th February.
ONE TWO THREE FOUR FIVE SIX SEVEN EIGHT NINE TEN CLICK THE NUMBERS IN SEQUENCE.
What time is it ? in the morning / in the afternoon in the evening
Global Metallized PP Films Industry 2015 Market Research Report “2015 Global Metallized PP Films Industry Report is a professional and in-depth research.
2B: Unit 5 What time is it What time is it ? o’clock / half past.
GMP Regulatory Perspective Dr. Pooja Mahadev Shirodkar Wallace Pharmaceuticals Pvt. Ltd. Date:
, International Regulatory and Health Authorities Inspections Maria Santaella Sr. Quality Director Janssen Ortho LLC Jansen Cilag Manufacturing LLC Gurabo,
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
References: Supply Chain Saves the World. Boston, MA: AMR Research (2006); Designing and Managing the Supply Chain – Concepts, Strategies and Case Studies;
Global Shower Gel Market Research Report and Industry Analysis
Global Gastric Bands Market Research Report and Industry Analysis
By Esra ARAS.
Pharmaceutical Quality in the 21st Century
What time is it? or What’s the time?.
CDRH 2010 Strategic Priorities
QUALITY CHALLENGES Rohan Patel Head of Quality Assurance
Using the Totally Awesome Teaching Strategies ®
Bio-Facility Qualification, Start-Up & Licensure
TWO MINUSES MAKE A PLUS (and other stories)
En la Clase – examen oral
  or 0. 1 one tenth.
NUMBERS one two three four five six seven eight
TO PAST TELLING THE TIME.
WHAT TIME IS IT? OK NO! It's o’clock A quarter past
National Medicines Policies
Numbers
CLICK THE NUMBERS IN SEQUENCE
Look at the clock. Thirteen One Fourteen Two Fifteen Three Sixteen
ISO
Presentation Title Presentation Title
ISO 9001.
What time is it ? o’clock / half past 2B: Unit 5.
STRIKE THE NUMBER! PLAY.
MATHS TIME! nine ten eleven fifteen eight
CLICK THE NUMBERS IN SEQUENCE
TIME PAST O’CLOCK TO HALF TO HALF O’CLOCK PAST.
Multiplication facts Your Help Guide.
National Medicines Policies
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
What’s the time? CLICK ON THE CLOCK.
GMP Legal Framework in Kyrgyzstan
Presentation transcript:

GMP Compliance Trends: An Industry Perspective Mitchell W. Manning Priorities Limited

GMP Compliance Trends: An Industry Perspective Presentation Context: Current Compliance Issues for Pharmaceuticals and Devices Presentation Sources: -FDA.gov- Wall Street Journal -ASQ- Fortune -ISPE- Harvard Business Review -PDA- Burrill & Company -Internet- Interviews Presentation Disclaimer: The information and opinions expressed by the presenter are intended for general training and educational use of the conference audience and are not intended as official positions of the ASQ/FDC-FDA.

GMP Compliance Trends: An Industry Perspective Trend One: GMP Compliant Manufacturing by Design Trend Two: Partnering With the Regulators Trend Three: Outsourcing Compliance Leadership Trend Four: Risk Management of Compliance Trend Five: Compliance through PAT Trend Six: Multiple Compliance Requirements Trend Seven: Going Global Trend Eight: Going High Tech Trend Nine: Risk Management of GMP Inspections Trend Ten: Over-committing and under-performing Trend Eleven: GMP Compliance to GMP Quality Trend Twelve: Risk Taking before Risk Management Trend Thirteen: Rx GMPs preferred over Dx GMPs

GMP Compliance Trends: An Industry Perspective Trend One: GMP Compliant Manufacturing by Design

Integrated Quality System DesignExecuteMonitor/Control Design – determine what is really important Execute – translate into manufacturing Monitor/Control – translate into quality assurance Continuous Improvement

Process Control and Capability Cycle Development History Technical Evaluations process and productQuality (GMP) Evaluations quality systems Integrated Validation Master Plan processproductsystems Change Control process and productChange Control quality systems Process Flow Document Technology Transfer Qualification Validationprocess and product Execute, Monitor and Control Quality Management System Begin with the End in Mind 1.Compliant 2.Capable 3.Robust 4.In Control 5.Continuously Improving Establish shared standards and expectations Execute and monitor with best business practices. Assess results against the standards and practices. Document with GMPs in Mind 1.Clear 2.Concise 3.Correct 4.Complete 5.Confident

GMP Compliance Trends: An Industry Perspective Trend Two: Partnering with the Regulators Drug Pipeline Globalization Bioterrorism Counterfeit Drugs and Devices Pandemics GMP Complexity Personalized Medicine

Burrill's Predictions for Biotech in Biotechnology will continue to fuel a major transformation in healthcare -- one that emphasizes earlier disease detection, more targeted treatments, and adjunctive support through enhanced nutrition. A reasonably robust public equity IPO market in the U.S. in 2006 and even a larger number internationally. More pricing pressure -- managed care, CMS, various country health ministries The trend towards Mergers and Acquisitions will continue with substantially more deals than 2005, especially among the larger companies. Similarly, we will see more and larger partnering deals with an emphasis towards discovery stage deals. Drug safety issues will be high on the agenda and approvals will be tougher to obtain. The trend towards personalized medicine will accelerate.

GMP Compliance Trends: An Industry Perspective Trend Three: Outsourcing Compliance Leadership

GMP Compliance Trends: An Industry Perspective Trend Four: Risk Management of Compliance

GMP Compliance Trends: An Industry Perspective Trend Five: Compliance through PAT

GMP Compliance Trends: An Industry Perspective Trend Six: Multiple Compliance Requirements

GMP Compliance Trends: An Industry Perspective Trend Seven: Going Global

GMP Compliance Trends: An Industry Perspective Trend Eight: Going High Tech

GMP Compliance Trends: An Industry Perspective Trend Nine: Risk Management of GMP Inspections

GMP Compliance Trends: An Industry Perspective Trend Ten: Over-committing and under-performing

GMP Compliance Trends: An Industry Perspective Trend Eleven: GMP Compliance to GMP Quality

GMP Compliance Trends: An Industry Perspective Trend Twelve: Risk Taking before Risk Management

GMP Compliance Trends: An Industry Perspective Trend Thirteen: Rx GMPs preferred over Dx GMPs Globalization of Standards Coming together of Regulators and Industry Inspectorate Partnering Control Processes through Validation Skills Competency Validation Resolving Problems